Dermal Application of Retinoic Acid Receptor Agonists for Amelioration of Hypertrophic Scar
US-2024245639-A1 · Jul 25, 2024 · US
US10022348B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10022348-B2 |
| Application number | US-201615225917-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 2, 2016 |
| Priority date | May 20, 2009 |
| Publication date | Jul 17, 2018 |
| Grant date | Jul 17, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and process of preparing it.
Opening claim text (preview).
We claim: 1. A method for treating acne, the method comprising: topically applying to the skin of a subject in need thereof, a solution composition consisting of: (i) isotretinoin or a pharmaceutically acceptable salt thereof as the sole active ingredient, the isotretinoin being present at a concentration of 0.05% or 0.1% by weight per volume of the total topical solution composition; (ii) a pharmaceutically acceptable vehicle selected from the group consisting of one or more of fatty acid esters, fatty acids or fatty alcohols in which the therapeutically effective amount of isotretinoin is soluble; and (iii) one or more pharmaceutically acceptable excipients, wherein the solution composition is substantially free of ethyl alcohol and the topical composition exhibits no skin irritation. 2. The method according to claim 1 , wherein the pharmaceutically acceptable excipient comprises one or more of colorants, fragrances, odor modifiers, viscosity modifiers, propellants, chelating agents, solubilizing excipients, penetration enhancers, preservatives, antioxidants, stabilizers, moisturizers, humectants, emollients, astringents, moisturizers, and mixtures. 3. The method according to claim 1 , wherein the composition is stable during storage at 40° C. and 75% RH and 25° C. and 60% RH for one month. 4. The method according to claim 1 , wherein the fatty acid esters comprise polyol esters of medium chain fatty acids. 5. The method according to claim 4 , wherein the polyol esters of medium chain fatty acids comprise esters and mixed esters of glycerol, propylene glycol, polyglycerol and polyethylene glycol with medium chain fatty acids and medium chain triglycerides, or a mixture thereof. 6. The method according to claim 5 , wherein the medium chain triglycerides comprise (C 6 -C 12 ) fatty acid esters of glycerol, or a mixture thereof. 7. The method according to claim 1 , wherein the fatty acids comprise C 6 -C 12 saturated or mono or di-unsaturated acids, or a mixture thereof. 8. The method according to claim 7 , wherein the fatty acids comprise oleic acid, linoleic acid, caprylic acid, caproic acid, or a mixture thereof. 9. The method according to claim 1 , wherein the fatty alcohols comprise C 6 -C 20 saturated or mono or di-unsaturated alcohols, or a mixture thereof. 10. The method according to claim 9 , wherein C 6 -C 20 saturated or mono or di-unsaturated alcohols comprise oleyl alcohol, capryl alcohol, capric alcohol, or a mixture thereof. 11. The method according to claim 1 , wherein the composition comprises propylene glycol dicaprylate/dicaprate and caprylic/capric triglyceride as the vehicle in which the isotretinoin is solubilized. 12. The method according to claim 1 , wherein the composition further comprises an antioxidant. 13. The method according to claim 12 , wherein the antioxidant comprises butylated hydroxyl anisole. 14. The method according to claim 1 , wherein the vehicle has an acid value less than 1, wherein the acid value comprises the number of milligrams of potassium hydroxide required to neutralize 1 gram of the topical solution composition. 15. The method according to claim 1 , wherein the vehicle in which the isotretinoin is solubilized is selected to be free of a burning sensation to the skin to which the vehicle is applied.
Retinoic acids {; Salts thereof} · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title
Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title
Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.